



RECEIVED

MAY - 11 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:  
Goodwin and Din

Docket No.: 2519

Serial No: 09/302,863

Group Art Unit: 1646

Filed: April 30, 1999

Examiner: D. Romeo

For: METHODS OF USE OF THE TACI/TACI-L INTERACTION

14/B  
15/3  
5/11/01

AMENDMENT PURSUANT TO 37 CFR § 1.312

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action mailed November 20, 2000, applicants respectfully request that the Examiner enter the following amendments in the referenced patent application, pursuant to 37 CFR §1.312. A copy of each replacement paragraph and claim, marked up to show the amendments, accompanies this amendment.

Applicants hereby petition for a two month extension of time within which to respond to the outstanding Restriction Requirement. Applicants authorize the Commissioner to charge Deposit Account no. 09-0089, the extension fee and any other fee due in connection with the enclosed amendment or to credit any overpayment, to our Deposit Account no. 09-0089. A duplicate of this paper is attached for that purpose.

AMENDMENTS

**In the Specification:**

On page 5, please delete the paragraph beginning at line 28 and replace it with the following paragraph:

β<sup>1</sup> The terms "TACI" and "TACI protein" are used interchangeably to define the TNF receptor disclosed by WO 98/39361 and refer, among others, generally to a polypeptide having the amino acid sequence set forth in SEQ ID NO:2 or homologous analogs thereof. TACI comprises an extracellular domain, a transmembrane domain, and cytoplasmic domain.

**Match & Return**